| Identification | Back Directory | [Name]
3-((1R,3S,5S)-3-((7-((5-Methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | [CAS]
2051918-33-1 | [Synonyms]
Izencitinib
Izencitinib（TD-1473）
8-Azabicyclo[3.2.1]octane-8-propanenitrile, 3-[[7-[(5-methyl-1H-pyrazol-3-yl)amino]-1,6-naphthyridin-5-yl]amino]-, (3-exo)-
3-((1R,3S,5S)-3-((7-((5-Methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | [Molecular Formula]
C22H26N8 | [MDL Number]
MFCD32173126 | [MOL File]
2051918-33-1.mol | [Molecular Weight]
402.51 |
| Chemical Properties | Back Directory | [Boiling point ]
691.8±55.0 °C(Predicted) | [density ]
1.337±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (124.22 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.02±0.10(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Uses]
Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis[1]. | [in vivo]
Izencitinib (TD-1473, 1 mg/kg BID) preserves body weight and reduced occult blood scores in a mouse oxazolone colitis model[1]. | [References]
[1] Kevin S Currie, et al. Small-molecule agents for the treatment of inflammatory bowel disease. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2034-2041. DOI:10.1016/j.bmcl.2019.06.042
[2] William J Sandborn, et al. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis. 2020 Sep 16;14(9):1202-1213. DOI:10.1093/ecco-jcc/jjaa049
[3] D. Beattie, et al. TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor. Journal of Crohn's and Colitis, Volume 10, Issue suppl_1, March 2016, Page S123. |
|
|